Current position

The Vanguard Group, Inc.’s Johnson & Johnson (JNJ) position

Reported position history, portfolio importance and verified filing changes from public SEC disclosures.

The Vanguard Group, Inc.Verified through Q4 2025
Relationship snapshot

At a glance

The full verified relationship, including prior ownership episodes and exits where supported.

First reportedQ1 2014Earliest verified positive filing snapshot
Latest statusCurrent positionBased on the latest supported relationship state
Peak shares247.48MHighest verified quarter-end share count
Quarters reported48Verified quarters with shares above zero
What happened?

The Vanguard Group, Inc. first reported Johnson & Johnson in Q1 2014. The reported position was increased and reduced across later filings. The Vanguard Group, Inc. currently reports 240.35M shares. The latest verified filing showed: Bought 1.6% more.

Verified SEC history

Position over time

See the same verified relationship through reported shares, portfolio weight or reported value.

Metric

Gaps indicate periods that cannot be safely connected or where a verified corporate action changes the raw share scale. Stock price, when available, is market context and not a transaction price.

Key filing events

What changed

Latest filing plus the most meaningful reported changes. Unchanged quarters are collapsed by default.

Q4 2025
Bought 1.6% more+3.73M shares · 240.35M shares reported after the change
Filing context

Quarter-end price $206.95

Q3 2025
Sold 0.2% of the position−429.27K shares · 236.62M shares remained
Filing context

Quarter-end price $185.42

Q2 2025
Bought 1.3% more+3.09M shares · 237.05M shares reported after the change
Filing context

Quarter-end price $152.75

Q1 2025
Bought 0.5% more+1.17M shares · 233.96M shares reported after the change
Filing context

Quarter-end price $165.84

Q4 2024
Bought 0.8% more+1.77M shares · 232.79M shares reported after the change
Filing context

Quarter-end price $144.62

Q3 2024
Bought 0.9% more+1.98M shares · 231.02M shares reported after the change
Filing context

Quarter-end price $162.06

Portfolio importance

How important is Johnson & Johnson in The Vanguard Group, Inc.’s reported portfolio?

Relative importance is measured only within the verified primary non-option reported portfolio for each quarter.

Current portfolio weight0.7%Q4 2025
Current rank#15of 4329 reported positions
Peak portfolio weight1.4%Q2 2016
Best historical rank#3Q2 2014
SEC evidence & methodology

SEC filing evidence

Market context and filing-derived values are kept separate from actual transaction prices, which 13F filings do not disclose.

Latest verified stock price$270.682026-09-24

Market context only; not an investor transaction price.

Latest filing quarter-end price$206.95Q4 2025

Derived from validated reported value and shares where supported.

Latest verified investor filingQ4 2025 · filed 2026-01-29
Open SEC filing ↗

View Johnson & Johnson stock page →

Coverage is bounded to Vanguard’s top reported positions and material events rather than every security in each Form 13F. The filing reflects reportable U.S.-listed holdings, not Vanguard’s complete global assets, fund-by-fund ownership, exact trade dates or execution prices.